M. Rissler

The need for comparative data in spondyloarthritis

B. Kirkham, G. Schett, M. Østergaard, 2019, Arthritis Research & Therapy.

Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study

K. Reich, J. Szepietowski, J. Szepietowski, 2020, The British journal of dermatology.

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial

L. Coates, L. Gossec, A. Mera-Varela, 2020, Annals of the Rheumatic Diseases.

Secukinumab for moderate‐to‐severe palmoplantar pustular psoriasis: Results of the 2PRECISE study

U. Mrowietz, D. Burden, H. Bachelez, 2019, Journal of the American Academy of Dermatology.

OP0235 SECUKINUMAB IMPROVES AXIAL MANIFESTATIONS IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NSAIDS: PRIMARY ANALYSIS OF THE MAXIMISE TRIAL

L. Coates, L. Gossec, X. Baraliakos, 2019, Oral Presentations.

Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial

A. Baranauskaitė, H. Marzo-Ortega, D. Poddubnyy, 2021, Therapeutic advances in musculoskeletal disease.

Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results

J. Szepietowski, M. Augustin, K. Kingo, 2020, Journal of the European Academy of Dermatology and Venereology.

Baseline characteristics of patients with moderate‐to‐severe psoriasis according to previous systemic treatment exposure: the PROSE study population

M. Augustin, U. Mrowietz, S. Gerdes, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Baseline characteristics of patients with moderate‐to‐severe psoriasis according to previous systemic treatment exposure: the PROSE study population

S. Gerdes, C. Sieder, D. Baeumer, 2020 .